Preview Mode Links will not work in preview mode

COVID-19 Evidence presented by InpharmD™


Apr 2, 2021

A randomized study conducted to determine the effect of bamlanivimab monotherapy and combination therapy with bamlanivimab and etesevimab on severe acute respiratory syndrome coronavirus 2(SARS-CoV-2) viral load in mild to moderate COVID-19